PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Haematology, University College London NHS Foundation Trust, London, UK.\', \'UCL Institute of Immunity and Transplantation, UCL, London, UK.\', \'CR UK & UCL Cancer Trials Centre, UCL Cancer Institute, UCL, London, UK.\', \'Department of Haematology, UCL Cancer Institute, London, UK.\', \'Centre for Cancer Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.\', \'Department of Clinical Virology, University College London NHS Foundation Trust, London, UK.\', \'UCLH NIHR Biomedical Research Centre, London, UK.\', \'Bloomsbury Institute of Intensive Care Medicine, UCL, London, UK.\', \'Department Immunology, Royal Free London Hospitals NHS Foundation Trust, London, UK.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1111/bjh.17027
?:doi
?:hasPublicationType
?:journal
  • British journal of haematology
is ?:pmid of
?:pmid
?:pmid
  • 32678948
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.036
?:rankingScore_hIndex
  • 169
is ?:relation_isRelatedTo_publication of
?:title
  • Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo- or immunotherapy.
?:type
?:year
  • 2020

Metadata

Anon_0  
expand all